

## **REMARKS/ARGUMENTS**

### **I. Status of the Claims**

Claims 1-15 have been canceled without prejudice. New Claims 16-20 are presented for consideration. New Claims 16-20 incorporate the limitations of Claims 1 and 11, and additionally include the limitation of the creation of a salt form of S-[2-[(1-Iminoethyl)-amino]ethyl]-2-methyl-L-cysteine.

Support for these Claims may be found, for example, on page one, paragraph 2, and page 5, paragraph 15.

No new matter has been added.

### **II. The New Claims are not obvious over Webber *et al.* in view of Puetter *et al.***

While Claims 16 through 20 are new, it is believed that the same obviousness rejection may be applied. Therefore, the following statement addresses this rejection as it was applied to canceled Claims 1-15.

Webber *et al.*, does not disclose the use of a membrane to separate S-[2-[(1-Iminoethyl)-amino]ethyl]-2-methyl-L-cysteine from any counterion.

Puetter *et al.*, does not describe a method to make a salt form from a neutral form of a compound. Therefore, it is believed that the presently claimed invention is not obvious over Webber *et al.* in view of Puetter *et al.*

### **III. Conclusion**

If the Examiner believes a telephonic interview with Applicant's representative would aid in the prosecution of this application, the Examiner is cordially invited to contact Applicant's representative at the below listed number.

Respectfully submitted,

  
Philip B. Polster II

Attorney for Applicants

Reg. No. 43,864

PHARMACIA CORPORATION